New Tubulin Polymerization Inhibitor Derived from Thalidomide: Implications for Anti-Myeloma Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|15|8|754-765

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.15, Iss.8, 2008-04, pp. : 754-765

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Use of Thalidomide in Myeloma Therapy as an Effective Anticancer Drug

By  

Current Cancer Drug Targets, Vol. 6, Iss. 4, 2006-06 ,pp. : 325-331

Bentham Science Publishers

Access to resources Recommend Favorite

Imidazoles and Benzimidazoles as Tubulin-Modulators for Anti-Cancer Therapy

By  

Current Medicinal Chemistry, Vol. 22, Iss. 11, 2015-04 ,pp. : 1312-1323

Bentham Science Publishers

Access to resources Recommend Favorite

Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor

By Hsu Lih-Ching  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1379-1388

Springer Publishing Company

Access to resources Recommend Favorite

Thalidomide in multiple myeloma

By García-Sanz Ramón  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 2, 2006-02 ,pp. : 195-213

Informa Healthcare

Access to resources Recommend Favorite

Thalidomide in Multiple Myeloma

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 6, 2006-12 ,pp. : 431-440

Bentham Science Publishers

Access to resources Recommend Favorite